[European Drug Administration: Novo Nordisk said that the shortage of diabetes drugs will last until 2024] The European Drug Administration (EMA) released a note on November 21 local time, saying that Novo Nordisk said that due to capacity constraints and increased demand, the shortage of its diabetes drugs "Ozempic" and "Victoza" will worsen in the fourth quarter of 2023 and will continue until 2024. In order to increase the supply of Novotel, the company has decided to temporarily reduce the supply of Novotel.